Collapsin response mediator protein 4 promotor methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate
Autor: | Jun Pang, Xin Gao, Qiong Liang, Jian-Ning Chen, Zi-jin Weng, Qun-Xiong Huang, Jue Wang, Zheng Chen, Chun-Kui Shao |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2018 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty 030232 urology & nephrology Methylation lcsh:RC254-282 03 medical and health sciences chemistry.chemical_compound Prostate cancer 0302 clinical medicine Prostate Lactate dehydrogenase Internal medicine Genetics medicine lcsh:QH573-671 Lymph node Receiver operating characteristic business.industry lcsh:Cytology Area under the curve Primary malignant lymphoma prostate (PMLP) medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ROC curve Prostate-specific antigen medicine.anatomical_structure chemistry 030220 oncology & carcinogenesis Primary Research business Collapsin response mediator protein 4 (CRMP4) Predictor |
Zdroj: | Cancer Cell International, Vol 18, Iss 1, Pp 1-10 (2018) Cancer Cell International |
ISSN: | 1475-2867 |
DOI: | 10.1186/s12935-017-0484-9 |
Popis: | Background Primary malignant lymphoma of the prostate (PMLP) is prone to occur in the elderly, and it has no significant correlation with lactate dehydrogenase (LDH) and prostate specific antigen (PSA). Clinical symptoms and imaging data of PMLP remain unspecific, and its prognosis is poor. A previous result showed that collapsin response mediator protein 4 (CRMP4) promotor methylation can be used as a predictor for lymph node metastases in prostate biopsies. However, the relationship between CRMP4 promotor methylation and PMLP has not been studied. Methods We investigated the clinicopathological features of PMLP and the significance of CRMP4 methylation in PMLP. The clinical data and diagnosis information of 10 patients with PMLP were retrospectively analyzed. The CRMP4 promotor methylation level in paraffin-embedded tissues of the 10 patients with PMLP were determined and then compared to limited prostate cancer (LPCa) and its negative lymph node tissue [LPCa-LN (−) (10 cases)] and also to metastatic prostate adenocarcinoma (mPCa) and its positive lymph node tissue [mPCa-LN (+) (10 cases)]. Methylation of the CRMP4 promotor in each group was analyzed statistically. A receiver operating characteristic (ROC) curve was used to analyze the diagnostic value of CRMP4 methylation in PMLP. Results The average methylation value of CRMP4 in 10 PMLP patients, 20 cases of prostate adenocarcinoma tissue, 10 cases LPCa-LN (−) and 10 cases mPCa-LN (+) were 42.3, 30.6, 6.7 and 20.3%, respectively. A Kruskal–Wallis test showed that the difference of CRMP4 methylation was significant (X2 = 38.0, P 40.9% could diagnose PMLP. This method had 90% sensitivity and 95% specificity under conditions of CRMP4 methylation > 40.9%. The area under the curve (AUC) was 0.957. Conclusions Methylation of the CRMP4 gene was significantly increased in PMLP, and it is expected to become a new predictor for PMLP. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |